New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:01 EDTSGENSeattle Genetics announces ADCETRIS approval in Japan
Seattle Genetics announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma. As a result, Seattle Genetics will receive two milestone payments from Takeda totaling $9M upon final pricing agreement in Japan. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including ALCL. The approval of the new drug application was based on two global pivotal phase 2 clinical trials of ADCETRIS, as well as a phase 1/2 clinical trial conducted in Japan, for patients with relapsed or refractory CD30-positive HL and ALCL. In March 2012, the Japanese MHLW granted ADCETRIS orphan drug designation for the treatment of patients with HL and ALCL, which triggered priority review in Japan.
News For SGEN From The Last 14 Days
Check below for free stories on SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTSGENPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 8, 2014
09:03 EDTSGENSeattle Genetics to receive milestone payments from Takeda on Adcetris
Subscribe for More Information
07:35 EDTSGENNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use